Zai Lab Gross Margin 2016-2022 | ZLAB

Current and historical gross margin for Zai Lab (ZLAB) over the last 10 years. The current gross profit margin for Zai Lab as of March 31, 2022 is %.
Zai Lab Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2022-03-31 $0.17B $0.11B 64.33%
2021-12-31 $0.14B $0.09B 63.89%
2021-09-30 $0.12B $0.08B 67.83%
2021-06-30 $0.09B $0.06B 65.52%
2020-12-31 $0.04B $0.02B 63.16%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.927B $0.144B
Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company's product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00